Isodiol International (CSE:ISOL) has announced that it is a sponsor at the NY Cannabis World Congress & Business Expo.
As quoted in the press release:

This annual cannabis business event is held at the Jacob K. Javits Convention Center in NY and is the leading forum for doing business in one of the fastest growing industries in the United States.
“Isodiol is also honored to have Dr. Ron Aung-Din, a neurologist with over 35 years of experience in General Neurology and Neuro-Psychiatry, speaking about the positive benefits and advancements of phytocannabinoids and presenting IsoDerm, a premium product he developed along with the team at Isodiol,” said Isodiol’s CEO Marcos Agramont.
“Sponsoring this event along with having Dr. Ron Aung-Din present at the seminar, gives Isodiol key exposer to play an active roll in our industry and meet with global vendors and investors to speak firsthand with them about what we believe, which is, we are at the start of significant global operational highlights that will give our company a very strong foundation for customer engagement and retention, while accelerating Isodiol’s pace of innovation and competitive differentiation moving forward, with our brands like CBD Naturals, Iso-Sport, CannaCeuticals CBD Skincream, and Pot-O-Coffee,” said Agramont.

Click here to read the full press release.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less